Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
As a health professional, you need the leading dialysis products, renal pharmaceuticals and critical care solutions. Let's work together to find you the tools you need, so you can deliver the best care for patients.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
WALTHAM, Mass. – Oct. 14, 2019 – Fresenius Medical Care NorthAmerica (FMCNA), the nation’s leading provider of kidney care products and services, released the following statement in response to the signing of AB 290 in California:
“Fresenius Medical Care North America (FMCNA) is deeply saddened by Governor Newsom’s decision to sign AB 290. This is flawed legislation that will drastically impact California’s most vulnerable dialysis patients who rely on charitable premium assistance to support the affordability of their insurance coverage. We stand ready to support these patients and continue to provide superior dialysis care both in-center and at home.
“We hope that Assemblyman Wood and other proponents will work as hard as they did to pass this new law to ensure impacted patients can afford their increasing out-of-pocket costs and access to this life-sustaining care. This charitable support helps ensure vulnerable patients don’t have to choose paying for their healthcare over housing and food. We are also concerned that this law will result in patients only being able to access their life-saving care at hospitals due to lack of insurance coverage, and we will support these patients’ transitions to whatever extent possible. We offer our assistance to hospital systems and extend an open invitation to contract with them for trained dialysis staff, supply chain needs, and patient care transitions.”
About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.